Respiratory syncytial virus-specific adaptive immune system (RSV-specific adaptive immunity)

The Respiratory syncytial virus-specific adaptive immune system refers to the complex network of B cells and T cells that coordinate the body's defense against RSV infection (Nature Reviews Immunology, 2019). This system is responsible for generating neutralizing antibodies, primarily targeting the viral Fusion (F) and Attachment (G) glycoproteins, which are essential for viral entry and syncytia formation (NIH, 2023). Cellular immunity, mediated by CD4+ and CD8+ T cells, is crucial for clearing the virus and establishing immunological memory, though an imbalanced Th2-type response has been historically associated with vaccine-enhanced respiratory disease (ERD) (PubMed, 2022). Therapeutic interventions such as vaccines (e.g., Arexvy, Abrysvo) and monoclonal antibodies (e.g., Nirsevimab) aim to harness or supplement this system to prevent severe lower respiratory tract disease in vulnerable populations like infants and older adults (FDA, 2023). Understanding the nuances of this adaptive response is vital for developing safe and effective immunotherapies that avoid the pitfalls of immunopathology (StatPearls, 2023).

Other names

RSV adaptive immunityRSV-specific immune responseRSV-specific B-cell and T-cell responseAdaptive immunity to RSV

Induction of active immunity through vaccination or provision of passive immunity via monoclonal antibodies to neutralize viral particles and prevent infection.